Zenas BioPharma holds 2025 annual meeting; director Ting Xiao not re-elected, board reduced to 8

Zenas BioPharma, Inc.

Leon O. Moulder, Jr. and Hongbo Lu, Ph.D. elected as Class I directors for three-year terms.
Vote totals: Moulder 34,077,048 for; Lu 33,266,315 for; broker non-votes 1,467,979 each.
Board size reduced from 9 to 8 upon departure of Ting Xiao, who did not stand for re-election.
Ratification of Ernst & Young LLP as independent auditor for fiscal 2025 approved with 35,856,550 votes for.

item 5.02 item 5.07

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Ting (Tim) Xiao

Director

ZBIO · Zenas BioPharma, Inc.

Effective: 2025-06-10
Filed: June 12, 2025, 7:59 PM ET

Ting (Tim) Xiao did not stand for re-election at the expiration of his term ending at the Annual Meeting, and, accordingly, as of the conclusion of the Annual Meeting Mr. Xiao’s term ended with his resignation from the Board of Directors of the Company

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Ting (Tim) Xiao resigned as Director at Zenas BioPharma, Inc..

Action: resigned
Role: Director

Exact text from the filing

Ting (Tim) Xiao did not stand for re-election at the expiration of his term ending at the Annual Meeting, and, accordingly, as of the conclusion of the Annual Meeting Mr. Xiao’s term ended with his resignation from the Board of Directors of the Company

View on SEC.gov

Zenas BioPharma, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-25-058892

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.